Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck Signs Cancer Pact With Avalon

March 12, 2007 | A version of this story appeared in Volume 85, Issue 11

Merck has joined forces with Avalon Pharmaceuticals to discover and develop inhibitors for an undisclosed cancer target. Avalon will deploy its drug-screening platform to choose a set of compounds from Merck's library and identify hits against the cancer target. Avalon will then pick compound families to optimize into preclinical candidates. Those compounds will be handed off to Merck for clinical development and commercialization. The deal could be worth up to $200 million in milestones for Avalon.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.